Century Therapeutics Inc. Common Stock IPSC · Stock Open Century Therapeutics Inc. Common Stock in new tab
Century Therapeutics Inc. Common Stock Analysis (IPSC)
Is Century Therapeutics Inc. Common Stock a good investment? Century Therapeutics Inc. Common Stock (IPSC) is currently trading at 1.85 USD. Market analysts have a consensus price target of 4.75 USD. This suggests a potential upside from current levels.
Earnings Schedule: Century Therapeutics Inc. Common Stock is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.45.
Investor FAQ
Does Century Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Century Therapeutics Inc. Common Stock?
Century Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -0.93.
Company Profile
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Community Discussion